Quick Answer
MAXCYTE, INC. reported Common Stock Shares Outstanding of 106.79 million shares for the year ending 2025.
- MAXCYTE, INC. showed an increase of +1.0% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from MAXCYTE, INC.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: 84.72 million shares | Q3 2021: 100.43 million shares | Q1 2022: 101.51 million shares | Q2 2022: 101.66 million shares | Q3 2022: 101.90 million shares | Q1 2023: 102.90 million shares | Q2 2023: 103.13 million shares | Q3 2023: 103.55 million shares | Q1 2024: 104.41 million shares | Q2 2024: 104.82 million shares | Q3 2024: 105.30 million shares | Q1 2025: 106.31 million shares | Q2 2025: 106.59 million shares | Q3 2025: 106.64 million shares.
- Over the full 6 years of available data (2020 to 2025), MAXCYTE, INC.'s Common Stock Shares Outstanding has grown by 38.0%.
- Historical annual values: Fiscal year 2025: 106.79 million shares | Fiscal year 2024: 105.71 million shares | Fiscal year 2023: 103.96 million shares | Fiscal year 2022: 102.40 million shares | Fiscal year 2021: 101.20 million shares | Fiscal year 2020: 77.38 million shares.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: